SEC
AXSM icon

Seven Eight Capital’s Axsome Therapeutics AXSM Stock Holding History

Seven Eight Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,546
Closed -$948K – 58
2024
Q3 		$948K Buy
+10,546
New +$921K 0.09% 414
2023
Q2 		– Sell
-3,819
Closed -$236K – 493
2023
Q1 		$236K Sell
3,819
-9,071
-70% -$596K 0.05% 373
2022
Q4 		$994K Buy
12,890
+6,225
+93% +$372K 0.26% 126
2022
Q3 		$297K Buy
+6,665
New +$333K 0.06% 382
2022
Q1 		– Sell
-8,384
Closed -$317K – 522
2021
Q4 		$317K Sell
8,384
-18,816
-69% -$692K 0.06% 355
2021
Q3 		$897K Buy
+27,200
New +$1.06M 0.09% 330
2019
Q3 		– Sell
-8,818
Closed -$227K – 590
2019
Q2 		$227K Buy
+8,818
New +$177K 0.01% 548

Other funds holding AXSM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Seven Eight Capital's AXSM Position: Q4 2024 in Review

Seven Eight Capital sold out of Axsome Therapeutics (AXSM) in Q4 2024, closing a stake of 10,546 shares — an estimated $948K sold.

Seven Eight Capital first reported a position in AXSM in Q2 2019 and held it in 7 quarters. The position peaked at $994K in Q4 2022. 292 funds tracked by Wall St. Rank hold AXSM as of Q4 2024.

  • Seven Eight Capital reported no remaining Axsome Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Seven Eight Capital sold 10,546 Axsome Therapeutics shares in Q4 2024, an estimated $948K.
  • Seven Eight Capital first reported a position in Axsome Therapeutics in Q2 2019 and held it in 7 quarters.
  • Seven Eight Capital's Axsome Therapeutics position peaked at $994K in Q4 2022.
  • 292 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2024.

Based on Seven Eight Capital's 13F filing for Q4 2024.